Sansure Biotech Inc (688289) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Sansure Biotech Inc (688289) has a cash flow conversion efficiency ratio of 0.008x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥59.72 Million ≈ $8.74 Million USD) by net assets (CN¥7.22 Billion ≈ $1.06 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Sansure Biotech Inc market cap and net worth for the company's overall valuation and market capitalisation.
Sansure Biotech Inc - Cash Flow Conversion Efficiency Trend (2017–2025)
This chart illustrates how Sansure Biotech Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Sansure Biotech Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Sansure Biotech Inc ranked by their cash flow conversion efficiency. Explore Sansure Biotech Inc earnings quality ratio to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
PM Capital Global Opportunities Fund Ltd
AU:PGF
|
-0.027x |
|
Clearway Energy Inc
NYSE:CWEN-A
|
0.072x |
|
Parade Technologies Ltd
TWO:4966
|
0.024x |
|
Better Life Commercial Chain Share Co Ltd
SHE:002251
|
0.006x |
|
Central Plaza Hotel Public Company Limited
BK:CENTEL-R
|
0.057x |
|
Arlo Technologies
NYSE:ARLO
|
0.072x |
|
Neway CNC Equipment Suzhou Co Ltd
SHG:688697
|
0.046x |
|
Wolverine World Wide Inc
NYSE:WWW
|
-0.192x |
Annual Cash Flow Conversion Efficiency for Sansure Biotech Inc (2017–2025)
The table below shows the annual cash flow conversion efficiency of Sansure Biotech Inc from 2017 to 2025. View current stock price of Sansure Biotech Inc for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | CN¥16.75 Billion ≈ $2.45 Billion |
CN¥183.96 Million ≈ $26.92 Million |
0.011x | -70.60% |
| 2024-12-31 | CN¥7.35 Billion ≈ $1.07 Billion |
CN¥274.45 Million ≈ $40.16 Million |
0.037x | +145.88% |
| 2023-12-31 | CN¥7.42 Billion ≈ $1.09 Billion |
CN¥112.82 Million ≈ $16.51 Million |
0.015x | -95.54% |
| 2022-12-31 | CN¥7.51 Billion ≈ $1.10 Billion |
CN¥2.56 Billion ≈ $374.45 Million |
0.341x | +15.80% |
| 2021-12-31 | CN¥6.38 Billion ≈ $933.79 Million |
CN¥1.88 Billion ≈ $274.67 Million |
0.294x | -47.17% |
| 2020-12-31 | CN¥4.75 Billion ≈ $694.40 Million |
CN¥2.64 Billion ≈ $386.65 Million |
0.557x | +1285.39% |
| 2019-12-31 | CN¥557.48 Million ≈ $81.58 Million |
CN¥22.41 Million ≈ $3.28 Million |
0.040x | +58.21% |
| 2018-12-31 | CN¥396.29 Million ≈ $57.99 Million |
CN¥10.07 Million ≈ $1.47 Million |
0.025x | +115.67% |
| 2017-12-31 | CN¥378.99 Million ≈ $55.46 Million |
CN¥-61.44 Million ≈ $-8.99 Million |
-0.162x | -- |
About Sansure Biotech Inc
Sansure Biotech Inc. researches and develops, produces, and sells in vitro diagnostic reagents and instruments in China and internationally. It offers nucleic acid and multiple nucleic acid diagnostic kits for coronavirus, CoV-2, influenza virus, and respiratory syncytial virus; DNA fluorescence and nucleic acid diagnostic kits for respiratory tract infections, HPV infections, and reproductive tr… Read more